Jamie Cesanek | Authors


Long-Term Survival Benefit with Durvalumab in NSCLC Confirmed in Updated Findings

June 04, 2021

Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.